In immunosuppressed patients, BKPyV-variants emerge carrying rearranged non-coding control-regions (rr-NCCRs) that increase early viral gene region (EVGR) expression and replication capacity. BKPyV also encodes microRNAs, which have been reported to downregulate EVGR-encoded large T-antigen transcripts, to decrease viral replication in infected cells and to be secreted in exosomes. To investigate the interplay of NCCR and microRNAs, we compared archetype- and rr-NCCR-BKPyV infection in cell culture. We found that laboratory and clinical rr-NCCR-BKPyV-strains show higher replication rates but significantly lower microRNA levels than archetype virus intracellularly and in exosomes. To investigate whether rr-NCCR or increased EVGR activity modulated microRNA levels, we examined the (sp1-4)NCCR-BKPyV, which has an archetype NCCR-architecture but shows increased EVGR expression due to point mutations inactivating one Sp1 binding site. We found that microRNA levels following (sp1-4)NCCR-BKPyV infection were as low as in rr-NCCR-variants. Thus, NCCR rearrangements are not required for lower miRNA levels. Accordingly, Sp1 siRNA knock-down decreased microRNA levels in archetype BKPyV infection but had no effect on (sp1-4)- or rr-NCCR-BKPyV. However, rr-NCCR-BKPyV replication was downregulated by exosome preparations carrying BKPyV-microRNA prior to infection. To explore the potential relevance in humans, urine samples from 12 natalizumab-treated multiple sclerosis patients were analysed. In 7 patients, rr-NCCR-BKPyV were detected showing high urine BKPyV loads but low microRNAs levels, whereas the opposite was seen in 5 patients with archetype BKPyV. We discuss the results in a dynamic model of BKPyV replication according to NCCR activity and exosome regulation, which integrates immune selection pressure, spread to new host cells and rr-NCCR emergence.
Small-molecule drugs inhibiting BK polyomavirus (BKPyV) represent a significant unmet clinical need in view of polyomavirus-associated nephropathy or hemorrhagic cystitis which complicate 5% to 25% of kidney and hematopoietic cell transplantations. We characterized the inhibitory activity of acitretin on BKPyV-replication in primary human renal proximal tubular epithelial cells (RPTECs). Effective inhibitory concentration 50% (EC50) and 90% (EC90) were determined in dilution series measuring BKPyV loads, transcripts and protein expression, using cell proliferation, metabolic activity, and viability to estimate cytotoxic concentrations and selectivity indices (SI). Acitretin EC50 and EC90 in RPTECs were 0.64 (SI50 250) and 3.25 μM (SI90 49.2), respectively. Acitretin effectively inhibited BKPyV-replication until 72 h post-infection when added 24 h before until 12 h after infection, but decreased to <50% at later timepoints. Acitretin did not interfere with nuclear delivery of BKPyV genomes, but decreased large T-antigen transcription and protein expression. Acitretin did not inhibit the initial round of BKPyV-replication following transfection of full-length viral genomes, but affected subsequent rounds of re-infection. Acitretin also inhibited BKPyV-replication in human urothelial cells and in Vero cells, but not in COS-7 cells constitutively expressing SV40-large T-antigen. Retinoic acid-agonists (all-trans-retinoic acid, 9-cis-RA, 13-cis-RA, bexarotene, tamibarotene) and the RAR/RXR-antagonist RO41-5253 also inhibited BKPyV-replication, pointing to as yet undefined mechanism. Importance Acitretin selectively inhibits BKPyV-replication in primary human cell culture models of nephropathy and hemorrhagic cystitis. Since acitretin is an approved drug in clinical use reaching BKPyV-inhibiting concentrations in systemically treated patients, further studies are warranted to provide data for clinical repurposing of retinoids for treatment and prevention of replicative BKPyV-diseases.
Cell-penetrating peptides (CPPs) hold great promise for intracellular delivery of therapeutic proteins. However, endosomal entrapment of transduced cargo is a major bottleneck hampering their successful application. While developing a transducible zinc finger protein-based artificial transcription factor targeting the expression of endothelin receptor A, we identified interaction between the CPP and the endosomal membrane or endosomal entanglement as a main culprit for endosomal entrapment. To achieve endosomal disentanglement, we utilized endosome-resident proteases to sever the artificial transcription factor from its CPP upon arrival inside the endosome. Using this approach, we greatly enhanced the correct subcellular localization of the disentangled artificial transcription factor, significantly increasing its biological activity and distribution in vivo. With rational engineering of proteolytic sensitivity, we propose a new design principle for transducible therapeutic proteins, helping CPPs attain their full potential as delivery vectors for therapeutic proteins.
Tacrolimus (TAC) and mycophenolic acid (MPA) effectively reduce allograft rejection in kidney transplant recipients by inhibiting donor-specific lymphocyte activation and proliferation, respectively. However, this desired on-target effect is associated with uncontrolled BK polyomavirus (BKPyV)-replication and premature kidney allograft failure in 10%-20% of recipients. Besides impairing BKPyV-specific immunity, TAC also stimulates BKPyV-replication directly in renal proximal tubule epithelial cells (RPTECs) as an off-target effect. We now investigated off-target effects of MPA on BKPyV-replication in RPTECs. Following BKPyV exposure for 2 h, MPA inhibited BKPyV replication as shown by reduced supernatant BKPyV loads (IC 50 0.65 μM), number of infected cells, and viral protein expression at 72 hours post-infection (hpi). Notably, MPA inhibition of the viral large tumor antigen (LTag) was associated with the appearance of a truncated Tag of ∼17 kDa (truncTag-17). Adding guanosine (GUO) reversed MPA inhibition of BKPyV replication and viral protein expression, while truncTag-17 disappeared. Time course studies indicated that MPA inhibition was operative from 24 h before up to 24 h after BKPyV infection. GUO reversed MPA inhibition when administered from 24 h before to 24 h after BKPyV infection. Deep sequencing of passaged supernatant BKPyV genomes revealed more guanine-replacement (C→T or G→A) mutations for MPA compared to MPA/GUO (35% versus 10%, read threshold >0.5%). Thus, MPA can exert direct off-target effects on BKPyV replication in RPTECs linked to truncTag-17 expression, which can be partially reversed by exogenous GUO. Importance: Reducing immunosuppression is currently recommended for kidney transplant recipients with BKPyV-DNAemia and nephropathy to improve virus-specific immune control, but increases the risk of T-cell and antibody-mediated rejection. Although TAC and MPA synergize in their on-target effects on lymphocytes, they differ in their off-target effects on RPTECs. Unlike TAC, MPA inhibits BKPyV replication in an uncompetitive dose-dependent manner. MPA inhibition can be partially reversed by exogenous GUO using the purine salvage pathway that is lacking in lymphocytes. MPA acts during the early viral replication phase that depends on LTag promoting cellular G1→S-phase progression. MPA-mediated GUO depletion not only reduces rapid cell proliferation similar to the well-known gastrointestinal or hematopoietic toxicities, but also slows viral replication, induces expression of a truncTag-17, and increases GC-mutation rates in progeny virus genomes. We discuss the relevance of these off-target characteristics of MPA in the optimized management of kidney transplant recipients with BKPyV-DNAemia and -nephropathy.